s2682
NM_000610.3
NM_001001389.1
NM_001001390.1
NM_001001391.1
NM_001001392.1
NM_001202555.1
NM_001202556.1
NM_001202557.1
XM_005253231.2
XM_005253232.2
XM_005253233.2
XM_005253234.2
XM_005253235.2
XM_005253238.2
XM_005253239.2
XM_005253240.2
XM_006718388.1
XM_006718390.3
XM_011520482.1
XM_011520483.1
XM_011520484.1
XM_011520485.1
XM_011520486.1
XM_011520487.2
XM_011520488.1
XM_011520489.2
XM_017018583.1
XM_017018584.1
XM_017018585.1
4%(+/-0% mRNA remaining)(HeLa cell line) [TaqMan® Assay ID: Hs00174139_m1]
HeLa cells were reverse transfected with 5nM gene-specific Silencer® Select siRNA or 5nM Silencer® Select Negative Control #2 siRNA. 48 hours post-transfection, gene expression analysis was performed using the TaqMan® Gene Expression Cells-to-CT Kit and appropriate TaqMan® Gene Expression Assays. 18S rRNA was used as an endogenous control. Validation results are expressed as average percent mRNA remaining, relative to Negative Control siRNA-treated samples, along with the standard deviation of multiple independent experiments.